Drug giant Pfizer has pulled the plug on a late-stage clinical trial testing the efficacy of its cancer drug Sutent (sunitinib malate) in combination with the steroid prednisone in patients with prostate cancer. The trial was halted after an independent committee determined after an interim analysis that the combination was not likely to improve overall survival in patients compared to those receiving prednisone alone.
Last month, Pfizer announced that preliminary data from its SUN 1087 trial showed that Sutent plus Tarceva failed to improve overall survival in patients with non-small cell lung cancer.
Currently, Sutent is approved for gastrointestinal stromal tumors (GIST) and for renal cell carcinoma.
CANCER TYPE(S)
Prostate cancer
TREATMENT TYPE(S)
Multi-targeted receptor tyrosine kinase (RTK) inhibitor
Source
Seattle Genetics
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
